COLchicine Versus Ruxolitinib and Secukinumab in Open-label Prospective Randomized Trial in Patients With COVID-19

NCT04403243 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

70

Enrollment

OTHER

Sponsor class

Conditions

COVID 19

Interventions

DRUG: Colchicine
DRUG: Ruxolitinib 5 MG
DRUG: Secukinumab 150 MG/ML Subcutaneous Solution [COSENTYX]
OTHER: standard therapy

Sponsor

Lomonosov Moscow State University Medical Research and Educational Center